|
 |
|
|||||||
|
|||||||||
Diabetes 54:3442-3452, 2005
© 2005 by the American Diabetes Association, Inc.
Molecular Characterization of New Selective Peroxisome Proliferator–Activated Receptor 
Modulators With Angiotensin Receptor Blocking Activity
1 Center for Cardiovascular Research, Institute of Pharmacology and Toxicology, Charité Campus Mitte, Charité-Universitätsmedizin Berlin, Berlin, Germany
2 GENFIT, Parc Eurasante, Loos, France
3 Max-Planck Institute for Molecular Genetics, Berlin, Germany
4 Franz Volhard Clinic, HELIOS Hospital Berlin, Charité Campus Buch, Charité-Universitätsmedizin Berlin, Berlin, Germany
5 Department of Atherosclerose, Faculty of Pharmacy, Institute Pasteur Lille, University Lille II, UR 545 Institut National de la Santé et de la Recherche Médicale, Lille, France
Selective peroxisome proliferator–activated receptor (PPAR) 
modulation is a new pharmacological approach that, based on selective receptor-cofactor interactions and target gene regulation, should result in potent insulin sensitization in the absence of PPAR-mediated adverse effects. Here, we characterize two angiotensin receptor blockers (ARBs), telmisartan and irbesartan, as new selective PPAR modulators (SPPARMs). Analysis of PPAR protein conformation using protease protection showed that telmisartan directly interacts with the receptor, producing a distinct conformational change compared with a glitazone. Glutathione S-transferase pull-down and fluorescence resonance energy transfer assays revealed selective cofactor binding by the ARBs compared with glitazones with an attenuated release of the nuclear receptor corepressor and absence of transcriptional intermediary factor 2 recruitment by ARBs. Consistently, selective cofactor binding resulted in differential gene expression profiles in adipocytes (ARB versus glitazone treated) assessed by oligo microarray analysis. Finally, telmisartan improved insulin sensitivity in diet-induced obese mice in the absence of weight gain. The present study identifies two ARBs as new SPPARMs. SPPARM activity by ARBs could retain the metabolic efficacy of PPAR activation with reduction in adverse effects exerting in parallel AT1 receptor blockade. This may provide a new therapeutic option for better cardiovascular risk management in metabolic diseases and may initiate the development of new classes of drugs combining potent antihypertensive and antidiabetic actions.
Address correspondencereprint requests to Ulrich Kintscher, MD, Center for Cardiovascular Research, Institute of PharmacologyToxicology, CCM Charité-Universitätsmedizin Berlin, Hessische Str., 3-4 10115 Berlin, Germany. E-mail: ulrich.kintscher{at}charite.de
Abbreviations: ARB, angiotensin type 1 receptor blocker; AT1R, angiotensin type 1 receptor; FRET, fluorescence resonance energy transfer; GST, glutathione S-transferase; ITT, insulin tolerance test; LBD, ligand binding domain; NCoR, nuclear receptor corepressor; PPAR, peroxisome proliferator–activated receptor; PPRE, PPAR response element; RPE, R-phycoerythrin; SPPARM, selective PPAR modulators; TIF-2, transcriptional intermediary factor-2; TZD, thiazolidinedione
CiteULike 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  M. Clemenz, N. Frost, M. Schupp, S. Caron, A. Foryst-Ludwig, C. Bohm, M. Hartge, R. Gust, B. Staels, T. Unger, et al. Liver-Specific Peroxisome Proliferator-Activated Receptor {alpha} Target Gene Regulation by the Angiotensin Type 1 Receptor Blocker Telmisartan Diabetes, May 1, 2008; 57(5): 1405 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. C. Carmona, K. Louche, B. Lefebvre, A. Pilon, N. Hennuyer, V. Audinot-Bouchez, C. Fievet, G. Torpier, P. Formstecher, P. Renard, et al. S 26948: a New Specific Peroxisome Proliferator Activated Receptor {gamma} Modulator With Potent Antidiabetes and Antiatherogenic Effects Diabetes, November 1, 2007; 56(11): 2797 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sookoian and C. J. Pirola Review: Genetics of the cardiometabolic syndrome: new insights and therapeutic implications Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 37 - 47. [Abstract] [PDF]
|
|
|
|
 |
|
 H.-M. Jin and Y. Pan Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy Nephrol. Dial. Transplant., July 1, 2007; 22(7): 1943 - 1949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zanchi, A. G. Dulloo, C. Perregaux, J.-P. Montani, and M. Burnier Telmisartan prevents the glitazone-induced weight gain without interfering with its insulin-sensitizing properties Am J Physiol Endocrinol Metab, July 1, 2007; 293(1): E91 - E95. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Feige, L. Gelman, D. Rossi, V. Zoete, R. Metivier, C. Tudor, S. I. Anghel, A. Grosdidier, C. Lathion, Y. Engelborghs, et al. The Endocrine Disruptor Monoethyl-hexyl-phthalate Is a Selective Peroxisome Proliferator-activated Receptor {gamma} Modulator That Promotes Adipogenesis J. Biol. Chem., June 29, 2007; 282(26): 19152 - 19166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schupp, J. C. Curtin, R. J. Kim, A. N. Billin, and M. A. Lazar A Widely Used Retinoic Acid Receptor Antagonist Induces Peroxisome Proliferator-Activated Receptor-{gamma} Activity Mol. Pharmacol., May 1, 2007; 71(5): 1251 - 1257. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Pravenec and T. W. Kurtz Molecular Genetics of Experimental Hypertension and the Metabolic Syndrome: From Gene Pathways to New Therapies Hypertension, May 1, 2007; 49(5): 941 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Bakris Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome: Response to O'Malley, Bouldin, and Riche Diabetes Care, April 1, 2007; 30(4): e24 - e24. [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Brown and J. Plutzky Peroxisome Proliferator Activated Receptors as Transcriptional Nodal Points and Therapeutic Targets Circulation, January 30, 2007; 115(4): 518 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Ruster and G. Wolf Renin-Angiotensin-Aldosterone System and Progression of Renal Disease J. Am. Soc. Nephrol., November 1, 2006; 17(11): 2985 - 2991. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Gilde, J.-C. Fruchart, and B. Staels Peroxisome Proliferator-Activated Receptors at the Crossroads of Obesity, Diabetes, and Cardiovascular Disease J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A24 - A32. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Araki, T. Masaki, I. Katsuragi, K. Tanaka, T. Kakuma, and H. Yoshimatsu Telmisartan Prevents Obesity and Increases the Expression of Uncoupling Protein 1 in Diet-Induced Obese Mice Hypertension, July 1, 2006; 48(1): 51 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sugimoto, N. R. Qi, L. Kazdova, M. Pravenec, T. Ogihara, and T. W. Kurtz Telmisartan But Not Valsartan Increases Caloric Expenditure and Protects Against Weight Gain and Hepatic Steatosis Hypertension, May 1, 2006; 47(5): 1003 - 1009. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Diabetes | Diabetes Care | Clinical Diabetes | Diabetes Spectrum |